Benefit-Risk Determination is the structured analysis that weighs a medical device’s expected clinical benefits against its residual risks for the device’s intended purpose. Manufacturers and regulators use it to decide whether a device can be placed on the market and stay there. Under EU MDR 2017/745, it is a defined activity required for every device.
What is Benefit-Risk Determination?
Benefit-Risk Determination is the documented judgment that the medical benefits of a device outweigh the risks that remain after risk controls are applied. EU MDR 2017/745 defines it in Article 2(24) as the analysis of all assessments of benefit and risk relevant to the intended purpose. It sits across the whole product lifecycle, not at a single gate.
The same idea appears in risk management as benefit-risk analysis and, in regulatory submissions, as the basis for a reasonable assurance of safety and effectiveness. Benefit covers the positive clinical impact on a patient or on public health. Risk covers the probability and severity of harm. The determination is the documented conclusion that links the two.
Why Benefit-Risk Determination matters in medical device development
A device cannot be placed on the EU market if its benefits do not outweigh its risks in a documented analysis. That makes Benefit-Risk Determination a market-access gate, not a paperwork formality. A weak or missing analysis is a common reason notified bodies raise nonconformities during technical file review.
The stakes are direct. Patients carry any residual risk that the analysis fails to justify. Regulators can block approval, demand remediation, or trigger a field safety corrective action when post-market data shifts the balance. Rework late in a program costs far more than getting the analysis right during design. Audit exposure is real too, since the determination is one of the first records an assessor opens.
How Benefit-Risk Determination works
The determination pulls together evidence from risk management, clinical evaluation, and post-market data. ISO 14971:2019 governs the risk side: Clause 7.4 covers benefit-risk analysis for an individual residual risk, and Clause 8 covers the overall residual risk evaluation. ISO/TR 24971:2020 gives applied guidance.
A typical sequence:
- Define the intended purpose, patient population, and clinical claims.
- Identify benefits as measurable, patient-relevant outcomes per EU MDR Article 2(53).
- Estimate and evaluate risks using the ISO 14971 process, then apply risk controls.
- Characterize residual risk, both for single hazards and for the device as a whole.
- Weigh benefits against residual risks, drawing on clinical evidence and state of the art.
- Document the conclusion in the risk management report and clinical evaluation report (CER).
FDA frames the same exercise around reasonable assurance of safety and effectiveness. Its guidance, Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications, lists factors such as benefit magnitude, risk severity, and uncertainty. FDA does not recognize a single numerical benefit-risk ratio. The conclusion is a reasoned narrative supported by data.
Common challenges and best practices
The frequent failure is treating benefit as self-evident. Teams quantify risk in detail, then assert benefit in one vague sentence. Notified bodies push back when the benefit is not tied to measurable clinical outcomes. State current benefits in the same concrete terms you use for harms.
Another gap is letting the determination go stale. EU MDR Article 83 requires post-market surveillance data to update the benefit-risk determination, and the Periodic Safety Update Report (PSUR) must state its conclusions. Build that loop into your processes so new complaints, vigilance, and literature data actually move the analysis.
Good practice keeps the risk management report, CER, and post-market plan aligned on the same benefit and risk statements. Do not use economic or business advantage to justify a residual risk, since ISO 14971 does not permit it. Keep the reasoning traceable so an assessor can follow each conclusion back to its evidence.
How SJML helps with Benefit-Risk Determination
SJML supports Benefit-Risk Determination through its Compliance-as-a-Service and engineering work. The QARA team builds risk management files to ISO 14971, prepares clinical evaluation documents (CEP and CER), and runs post-market surveillance, including PMS and PSUR planning, vigilance, and CAPA. That keeps benefit and risk evidence connected from design through the field. SJML works across Class I, II, and III devices and aligns to FDA 21 CFR Part 820 and EU MDR, so the determination holds up across markets. Usability engineering to IEC 62366-1 feeds the same analysis.
Frequently asked questions
The terms overlap and are often used interchangeably. Benefit-risk analysis is the activity of weighing benefits against residual risks, described in ISO 14971:2019 Clause 7.4. Benefit-Risk Determination, the term EU MDR 2017/745 uses, is the overall analysis and documented conclusion for the device’s intended purpose. In practice, the analysis produces the determination.
Yes, in substance. FDA does not use the exact EU MDR phrase, but every premarket decision rests on a reasonable assurance of safety and effectiveness, which is a benefit-risk judgment. FDA guidance on benefit-risk determinations for premarket approval, De Novo, and investigational device exemption applications sets out the factors reviewers weigh. FDA does not recognize a single numerical ratio.
It is a lifecycle activity, not a one-time task. EU MDR Article 83 requires post-market surveillance data to update the determination, and class IIa and higher devices report conclusions in the PSUR, updated at least annually for class IIb and III. Update it whenever new clinical data, complaints, vigilance signals, or changes in the state of the art affect the balance.
ISO 14971:2019 governs the risk management analysis, with applied guidance in ISO/TR 24971:2020. EU MDR 2017/745 defines the term in Article 2(24) and requires it through the General Safety and Performance Requirements in Annex I and through clinical evaluation under Article 61. In the United States, FDA benefit-risk guidance documents apply to premarket submissions.
Related terms
- Risk Management (ISO 14971)
- Clinical Evaluation Report (CER)
- Post-Market Surveillance
- Residual Risk
- General Safety and Performance Requirements (GSPR)
